Quality of Life in Small Cell Lung Cancer Treatment
Author Information
Author(s): N.M. Bleehen, D.J. Girling, D. Machin, R.J. Stephens
Primary Institution: Medical Research Council Lung Cancer Working Party
Hypothesis
Can the number of chemotherapy courses for small cell lung cancer be reduced without compromising survival?
Conclusion
There was no major clinical gain from continuing chemotherapy beyond three courses or from using the ifosfamide regimen.
Supporting Evidence
- 59% of patients in the ECMV3 group experienced moderate or severe adverse reactions.
- 63% of patients had palliation of major symptoms like cough and haemoptysis.
- Anxiety levels fell substantially during treatment across all groups.
Takeaway
Doctors wanted to see if giving fewer chemotherapy treatments would still help people with lung cancer feel better. They found that giving more treatments didn't really help.
Methodology
Patients with small cell lung cancer were randomly assigned to three different chemotherapy regimens and assessed for quality of life and symptom palliation.
Potential Biases
Potential bias due to varying compliance rates among patients and centers.
Limitations
The trial did not allow for reliable comparisons between clinician and patient assessments of quality of life due to different assessment methods and timing.
Participant Demographics
Patients were from 21 centers in the UK, with varying performance statuses and disease extents.
Want to read the original?
Access the complete publication on the publisher's website